Novartis signs Voluntary License Agreement with the Medicine Patent Pool for Nilotinib
IPilogue
NOVEMBER 25, 2022
Pankhuri Malik is an Osgoode LLM Graduate, IPilogue Writer and IP Innovation Clinic Fellow. In a landmark development , Novartis has signed a Voluntary Licensing Agreement with the Medicine Patent Pool (MPP) for its nilotinib drug, used in treating Chronic Myeloid Leukemia (CML) in adults and children as young as a year old. Nilotinib is the first cancer treatment drug and the first drug for the treatment of non-communicable diseases to be voluntarily licensed in a public health initiative.
Let's personalize your content